Table 1.
Ongoing trials including patients carrying gastro-intestinal cancer with BRCA1m and/or BRCA2m and solid tumours with BRCA1m and/or BRCA2m
|
|
Study title
|
Design
|
Status
|
Trial description
|
| NCT03337087 | Liposomal irinotecan, fluorouracil, leucovorin calcium, and rucaparib in treating patients with metastatic pancreatic, colorectal, gastroesophageal, or biliary cancer | Phase I | Recruiting | Experimental: nal-IRI, leucovorin, fluorouracil, rucaparib |
| NCT02286687 | Talazoparib in treating patients with recurrent, refractory, advanced, or metastatic cancers and alterations in the BRCA genes | Phase IIa | Recruiting | Experimental: Talazoparib |
| NCT03428802 | Pembrolizumab in treating participants with metastatic, recurrent or locally advanced cancer and genomic instability | Phase IIa | Recruiting | Experimental: Pembrolizumab |
| NCT04503265 | A trial of AMXI-5001 for treatment in patients with advanced malignancies | Phase I-IIa | Recruiting | Experimental: AMXI-5001 (oral PARP and microtubule polymerization inhibitor) |
| NCT04171700 | A study to evaluate rucaparib in patients with solid tumors and with deleterious mutations in HRR genes (LODESTAR) | Phase IIa | Recruiting | Experimental: Rucaparib |
| NCT03415659 | Phase I clinical study of HWH340 tablet in patients with advanced solid tumors | Phase I | Recruiting | Experimental: HWH340 monotherapy |
| NCT02723864 | Veliparib (ABT-888), an Oral PARP inhibitor, and VX-970, an ATR inhibitor, in combination with cisplatin in people with refractory solid tumors | Phase I | Active, not recruiting | Experimental: VX-970 at Days 2 and 9 of each 21-d cycle; veliparib twice a day (BID) days 1-3 and 8-10 of each cycle; cisplatin at day 1 (and day 8 from DL3 onwards) of each cycle |
| NCT00516373 | A study to assess the safety and pharmacokinetics of an inhibitor of Poly ADP-Ribose Polymerase-1 (PARP) | Phase I | Active, not recruiting | Experimental: KU-0059436 (oral PARP inhibitor) |
| NCT04439227 | Testing AZD1775 as a potential targeted treatment in cancers with BRCA genetic changes (MATCH-Subprotocol Z1I) | Phase II | Active, not recruiting | Experimental: Adavosertib |
| NCT03565991 | Javelin BRCA/ATM: Avelumab plus talazoparib in patients with BRCA or ATM mutant solid tumors | Phase II | Active, not recruiting | Experimental: Combination of avelumab and talazoparib |
| NCT01482715 | A study of oral rucaparib in patients with a solid tumor (Phase I) or with gBRCA mutation ovarian cancer (Phase II) | Phase I-IIa | Completed | Experimental: Rucaparib |
| NCT01989546 | Pilot trial of BMN 673, an oral PARP Inhibitor, in patients with advanced solid tumors and deleterious BRCA mutations | Phase I-IIa | Completed | Experimental: Talazoparib (BMN 673) |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in patients with advanced or recurrent solid tumors | Phase I | Completed | Experimental: Talazoparib |
| NCT03767075 | A modular multi-basket trial to improve personalized medicine in cancer patients (BoB) | Phase II | Recruiting | Experimental: Atezolizumab |
nal-IRI: Lyposomal irinotecan; PARP: Poly-ADP ribose polymerase; ATR: Ataxia telangiectasia and Rad3-related protein; ATM: Ataxia telangiectasia mutated; BID: Bis in die; DL3: Dose level 3; BoB: Basket of baskets.